Literature DB >> 28985276

Mortality and Macrovascular Risk in Elderly With Hypertension and Diabetes: Effect of Intensive Drug Therapy.

Arseniy P Yashkin1, Julia Kravchenko2, Anatoliy I Yashin1, Frank Sloan3.   

Abstract

BACKGROUND: This study identifies the effect of intensive drug therapy (IDT) in individuals age 65+ with diabetes (type 2 diabetes mellitus (T2D)) and hypertension on all-cause death, congestive heart failure (CHF), hospitalization for myocardial infarction (MI), and stroke or transient ischemic attack (TIA).
METHODS: Individuals from the Medicare 5% dataset with hypertension and T2D undergoing IDT for these conditions were propensity score matched to a nonintensive drug-therapy group. Hazard ratios (HRs) were obtained using the Cox proportional hazard model.
RESULTS: IDT was associated with increased risk of CHF (HR 2.32; 95% confidence interval (CI) 2.32-2.38), MI (HR 4.27; 95% CI 4.05-4.52), and stroke or TIA (HR 1.80; 95% CI 1.70-1.89) but decreased risk of death (HR 0.95; 95% CI 0.93-0.97). Risk for CHF (HR 0.73; 95% CI 0.71-0.73), MI (HR 0.64; 95% CI 0.62-0.67), stroke or TIA (HR 0.82; 95% CI 0.78-0.86), and death (HR 0.29; 95% CI 0.28-0.29) was decreased by adherence to diabetes management guidelines.
CONCLUSIONS: Use of IDT in a high-risk population delays death but not severe macrovascular outcomes. Protective effects of IDT in high-risk patients likely outweigh polypharmacy-related health concerns. © American Journal of Hypertension, Ltd 2017. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  adherence; blood pressure; diabetes mellitus; hypertension; intensive drug therapy; macrovascular outcomes; mortality

Mesh:

Substances:

Year:  2018        PMID: 28985276      PMCID: PMC5861534          DOI: 10.1093/ajh/hpx151

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   3.080


  33 in total

1.  A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study.

Authors:  Peter C Austin; Paul Grootendorst; Geoffrey M Anderson
Journal:  Stat Med       Date:  2007-02-20       Impact factor: 2.373

2.  Executive summary: Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

3.  Incidence and preventability of adverse drug events among older persons in the ambulatory setting.

Authors:  Jerry H Gurwitz; Terry S Field; Leslie R Harrold; Jeffrey Rothschild; Kristin Debellis; Andrew C Seger; Cynthia Cadoret; Leslie S Fish; Lawrence Garber; Michael Kelleher; David W Bates
Journal:  JAMA       Date:  2003-03-05       Impact factor: 56.272

Review 4.  Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.

Authors:  George Dailey
Journal:  Clin Ther       Date:  2011-06       Impact factor: 3.393

Review 5.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

6.  Prevalence of multiple chronic conditions in the United States' Medicare population.

Authors:  Kathleen M Schneider; Brian E O'Donnell; Debbie Dean
Journal:  Health Qual Life Outcomes       Date:  2009-09-08       Impact factor: 3.186

7.  Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data.

Authors:  Sean Hennessy; Charles E Leonard; Cristin P Freeman; Rajat Deo; Craig Newcomb; Stephen E Kimmel; Brian L Strom; Warren B Bilker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-06       Impact factor: 2.890

8.  A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy.

Authors:  J T Hanlon; M Weinberger; G P Samsa; K E Schmader; K M Uttech; I K Lewis; P A Cowper; P B Landsman; H J Cohen; J R Feussner
Journal:  Am J Med       Date:  1996-04       Impact factor: 4.965

9.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

10.  Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio deJaneiro Type 2 Diabetes Cohort Study.

Authors:  Claudia R L Cardoso; Marcel T Ferreira; Nathalie C Leite; Gil F Salles
Journal:  Diabetes Care       Date:  2013-07-22       Impact factor: 19.112

View more
  4 in total

1.  Prevalence and factors associated with type 2 diabetes mellitus and hypertension among the hill tribe elderly populations in northern Thailand.

Authors:  Tawatchai Apidechkul
Journal:  BMC Public Health       Date:  2018-06-05       Impact factor: 3.295

2.  Traditional Chinese Patent Medicine for Primary Hypertension: A Bayesian Network Meta-Analysis.

Authors:  Zhe Chen; Qingyang Shi; Lizi Tan; Yingying Peng; Chunxiang Liu; Junhua Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-24       Impact factor: 2.629

3.  Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms.

Authors:  Lan Cheng; Qianyu Fu; Longhua Zhou; Yuqin Fan; Fenfen Liu; Yuanyuan Fan; Xin Zhang; Weiqing Lin; Xiaohe Wu
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.379

4.  Dose-Response Relationships Between Polypharmacy and All-Cause and Cause-Specific Mortality Among Older People.

Authors:  Yun-Ting Huang; Andrew Steptoe; Li Wei; Paola Zaninotto
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-05-05       Impact factor: 6.591

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.